Abstract:Abstract Introduction: Despite the numerous drugs available for patients with metastatic colorectal cancer (mCRC), median overall survival for this group of patients remains at ~20-24 months, with no significant advances in the last 7 years. In the US ~50,000 patients die each year from mCRC refractory to systemic therapy. Inhibiting angiogenesis as a therapy has led to a great deal of enthusiasm. However, the overall benefit of classical-antiangiogenic therapy remains modest and has not lived up to their expectations in treating CRC. Our recent studies suggest that VEGF intracrine signaling, rather than autocrine/paracrine signaling, regulates cell survival in CRC cells. Further studies to understand the significance and mechanisms of this novel function have led us to identify factors that intracellularly interact with VEGF. Our studies further indicate that one such interacting protein, SPECC1L, may have a significant role in CRC cell proliferation and may be a potential target in mCRC therapy. Methods: Lysates from CRC cells expressing Myc-tagged VEGF protein were immunoprecipitated and analyzed by mass spectrometry to identify VEGF-interacting protiens. SPECC1L was identified as a co-precipitated protein with high level of confidence. SPECC1L was depleted using siRNA and effects of such depletion on CRC cell growth and morphology were measured by cell growth assays (MTT), microscopy, FACS and western blot analyses. Localization of the protein and its interaction with microtubules and actin were visualized by immunostaining of FLAG-tagged recombinant SPECC1L protein. Results: SPECC1L was identified as a protein that co-immunoprecipitated with Myc-tagged VEGF in CRC cells using mass spectroscopy. Previous literature suggests a role for SPECC1L in cell division. As a fraction of VEGF overexpressing CRC cells have a large multinucleated phenotype, likely arising due to defects in cell division, it was hypothesized that a VEGF mediated regulation of SPECC1L may lead to such phenotype. Depletion of SPECC1L by siRNAs in multiple CRC cell lines led to strong defects in cell division. The effects of SPECC1L depletion were manifested as accumulation of doublet-cells failing to complete cytokinesis following mitosis and resulted in reduced cell proliferation. Failure to complete cell division also led to the formation of multinucleated cells and enhanced cell death. Conclusions: Inhibition of SPECC1L strongly inhibits CRC cell proliferation and enhances cell death. Thus targeting SPECC1L has the potential for developing therapeutics that reduce viability of CRC cells and improve survival of colorectal cancer patients. *** These studies were supported by the Gillson-Longenbaugh Foundation. Citation Format: Rajat Bhattacharya, Ling Xia, Fan Fan, Rui Wang, Delphine Boulbes, Xiang-Cang Ye, David Hawke, Lee Ellis. Depletion of SPECC1L inhibits colorectal cancer cell proliferation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3474. doi:10.1158/1538-7445.AM2017-3474

Abstract 6607: Serine depletion promotes antitumor immunity throughmitochondrial DNA-mediated cGAS/STING1 activation

Serine Depletion Promotes Anti-Tumor Immunity by Activating Mitochondrial DNA-mediated cGAS-STING Signaling

Serine Depletion Promotes Antitumor Immunity by Activating Mitochondrial DNA-Mediated cGAS-STING Signaling

An Immunometabolic Route for Activating cGAS/STING to Drive Anticancer Immunity

Abstract 3474: Depletion of SPECC1L Inhibits Colorectal Cancer Cell Proliferation

Deoxysphingolipids activate cGAS-STING in colon cancer cells and enhance tumor immunity

Serine Metabolic Reprogramming in Tumorigenesis, Tumor Immunity, and Clinical Treatment.

Exogenous and Endogenous Sources of Serine Contribute to Colon Cancer Metabolism, Growth, and Resistance to 5-Fluorouracil

Metabolic regulation of the mitochondrial immune checkpoint

Abstract 6608: Therapeutic enzyme depletion of L-serine for the treatment of serine auxotrophic tumors

Abstract LB349: Cysteine restriction enhances antitumor immunity in colorectal cancer

Abstract 6598: Inhibition of cGAS as a strategy to restore anti-tumor immunity response to STING agonist in chromosomally unstable tumors

Decoding Serine Metabolism: Unveiling Novel Pathways for Evolving Cancer Therapies

RESPIRATION DEFECTS LIMIT SERINE SYNTHESIS REQUIRED FOR LUNG CANCER GROWTH AND SURVIVAL

Abstract 6678: Microbial regulation of anti-tumor immunity in colorectal cancer

Abstract 7463: Chromosomal instability elicits anti-tumor immunity in pancreatic cancer

Abstract 295: Targeting spermine synthase triggers lipid metabolism reprogramming as a new therapeutic option to combat colorectal cancer

Serine Promotes the Progression of Esophageal Cancer Through Regulating One-Carbon Metabolism

Serine and one-carbon metabolism in cancer

Abstract SY41-03: Cancer specific amino acid metabolism

Serine Catabolism Regulates Mitochondrial Redox Control During Hypoxia